Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
复制标题
DOI：
10.1200/jco.1997.15.3.1218
复制
发表时间：
1997-03-01
影响因子：
45.3
通讯作者：
VadhanRaj, S
中科院分区：
文献类型：
--
作者：
Glaspy, J;Bukowski, R;VadhanRaj, S
目的：研究Procrit （epoetin alfa; Amgen Inc ., Thousand Oaks， CA）对接受化疗的贫血癌患者生活质量、输血需求和血红蛋白的影响。患者和方法：500多名社区肿瘤学家在一项开放标签研究中招募了2342名接受细胞毒性化疗的恶性肿瘤患者。患者每周3次给予促生成素150 U/kg治疗，如果认为治疗反应不足，可加倍治疗，总治疗时间长达4个月。结果：在入组的2342例患者中，有2030例患者的数据可用。在2,030名患者中，1,047名患者完成了所有4个月的促生成素治疗。促生成素与能量水平、活动水平和整体生活质量的平均自评分数显著增加有关；这些改善与血红蛋白增加的幅度相关，与肿瘤反应无关。此外，促生成素与平均血红蛋白显著升高以及需要输血的患者比例显著降低相关（基线至最终值，P < 0.001）。促生成素耐受性良好。结论：促生成素可有效改善白血病化疗患者的功能状态和生活质量，提高血红蛋白水平，降低输血需要量。功能状态的改善可归因于血红蛋白水平的增加，这表明通过积极治疗贫血可以改善这组患者的生活质量。需要进一步的研究来确定促生成素的最佳剂量和时间表。(C) 1997年由美国临床肿瘤学会。
Purpose: To study the impact of Procrit (epoetin alfa; Amgen Inc, Thousand Oaks, CA) on quality of life, transfusion requirements, and hemoglobin in anemic cancer patients receiving chemotherapy.Patients and Methods: More than 500 community-based oncologists enrolled 2,342 patients with malignancies undergoing cytotoxic chemotherapy in an open-label study. Patients were treated with epoetin alfa 150 U/kg three times weekly, which could be doubled if the therapuetic response was judged inadequate, Total treatment was up to 4 months.Results: Of the 2,342 patients enrolled, data were available for 2,030 patients. Of the 2,030, 1,047 patients completed all 4 months of epoetin alfa therapy. Epoetin alfa wets associated with significant increases in mean self-rated scores for energy level, activity level, and overall quality of life; these improvements correlated with the magnitude of the hemoglobin increase and were independent of tumor response. In addition, epoetin alfa was associated with a significant increase in mean hemoglobin and with a significant decrease in the proportion of patients requiring transfusions (baseline to final value, P < .001). Epoetin alfa was well tolerated.Conclusion: Epoetin alfa is effective in improving the funtional status and quality of life in anemic cancer patients receiving chemotherapy, as well as increasing hemoglobin level and decreasing transfusion requirements. Improvement in functional status con be attributed to an increase in hemoglobin level, demonstrating that quality of life in this group of patients can be improved by aggressively treating anemia. Further studies will be required to define the optimal doses and schedules for epoetin alfa. (C) 1997 by American Society of Clinical Oncology.